Ablative Solutions, Inc., was founded in 2011.
Reinventing renal denervation to improve cardiovascular health.
Ablative Solutions is passionately committed to enhancing and extending patients’ lives. We develop innovative and novel renal denervation solutions to deliver the treatment of choice for patients and their healthcare providers.
Our Core Values
- I am an Ambassador of our Culture and Reputation
- I Act with Integrity and Honesty
- I Take Pride In My Work
- I Challenge Myself and Others
- Together We Win!!!
Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea.1, 2 The Peregrine System Infusion Catheter provides physicians with a way to infuse diagnostic and therapeutic agents into the area surrounding the renal artery, where sympathetic nerves are located.
The Company is conducting two randomized sham-controlled trials using the Peregrine System Kit, which includes the Peregrine Catheter and Ablative Solutions dehydrated alcohol, for the treatment of hypertension with alcohol-mediated renal denervation. The TARGET BP OFF-MED Clinical Trial and the TARGET BP I Clinical Trial are both being conducted in the US and Europe. The TARGET BP I Clinical Trial is actively enrolling patients (www.targetbp1.com).
1 Fisher et al, Central Sympathetic Overactivity: Maladies and Mechanisms, Auton Neurosci. 2009 June 15; 148(1-2): 5–15. doi:10.1016/j.autneu.2009.02.003
2 Schmieder et al, European Society of Hypertension Position Paper on Renal Denervation 2018, Journal of Hypertension 2018 Oct;36(10):2042-2048